Lung cancer is the leading cause of cancer death in the USA with a 5-year survival rate of only 17.4% \[[@B1]\]. This is clearly illustrated by the 2015 lung cancer prevalence data for the USA, which reported an estimated number of 221,200 new cases, projected to result in 158,040 deaths \[[@B2]\]. With respect to type of malignancy, approximately 85% of lung cancers are classified as non-small cell lung cancer (NSCLC), comprised of two major types according to histological analysis, namely squamous and nonsquamous. At the time of diagnosis, half of these patients already have distant metastatic disease with a 5-year survival rate of less than 5%. Although the use of platinum-based chemotherapy has produced objective responses, only small improvements in survival are evident in patients with metastatic disease. In the case of those patients who relapse, second-line therapy may be considered \[[@B3]\]. However, the gravity of this situation is illustrated by the findings of a meta-analysis of five trials, which assessed the efficacy and safety of second-line chemotherapy with docetaxel and reported a median survival time of approximately 26 weeks \[[@B4]\]. An analysis of two other studies also noted small improvements with second-line pemetrexed therapy, but only in patients with nonsquamous NSCLC \[[@B5]\]. Although the use of pemetrexed is associated with similar outcome and less toxicity compared with docetaxel \[[@B6]\], the improvements in survival are still minor and are also associated with severe toxicities \[[@B4],[@B5]\]. Until recently, the treatment of progressive metastatic NSCLC clearly represented a very considerable unmet medical need, which, mercifully, has been alleviated by innovations in the field of onco-immunotherapy, specifically the availability of monoclonal antibodies that target key immune checkpoint inhibitory (ICI) molecules.

In this context, the availability and clinical efficacy of nivolumab, a fully human IgG4 monoclonal antibody that binds to and blocks activation of the ICI, programmed cell death protein 1 (PD-1) expressed on antitumor effector T cells, has revitalized the treatment of NSCLC \[[@B7]\]. Nivolumab has been approved in the USA since 2015 for the treatment of advanced squamous and nonsquamous NSCLC for those patients whose disease has progressed either on or after platinum-based chemotherapy \[[@B8],[@B9]\]. Although measurement of the level of tumor expression of PD-1 ligand (PD-L1) can guide clinicians to predict and select patients that are likely to respond to checkpoint inhibition, not all patients with PD-L1 levels ≥50% respond to this treatment modality \[[@B10]\]. Despite the availability of nivolumab, its success rate in the treatment of NSCLC is therefore somewhat disappointing. This contention is underscored by a recent pooled analysis of data from four clinical studies of nivolumab immunotherapy of previously treated NSCLC, encompassing 664 patients, that revealed an estimated 4-year overall survival (OS) rate of 14% compared with 5% in those treated with docetaxel \[[@B11]\]. Interestingly, however, of those nivolumab-treated patients who achieved a complete or partial response (PR) at 6 months, the subsequent 4-year survival was 56% \[[@B11]\]. This latter observation seemingly indicates the existence of determinants of the efficacy of nivolumab-based immunotherapy of NSCLC, which, if identified prior to implementation of therapy, may distinguish those patients most likely to achieve benefit, while revealing potential adjunctive therapies for those who not.

One such determinant of the responsiveness of cancer patients to ICI-targeted therapy is the circulating neutrophil/lymphocyte ratio (NLR), defined as the quotient of the baseline absolute peripheral neutrophil and lymphocyte counts \[[@B12]\]. Importantly, the NLR is an inexpensive and easily measured biomarker that is readily accessible to cancer specialists. Indeed the NLR is now well recognized as a biomarker of cancer-related inflammation, and has been shown in the pre-immunotherapy era to have prognostic relevance across a large variety of tumor types, including colorectal, gastric, pancreatic, NSCLC, hepatocellular, ovarian, cervical and renal cancers, when measured prior to initiation of chemotherapy, chemoradiation or surgical resection \[[@B12]\].

Various studies have also explored the prognostic utility of the NLR in patients with NSCLC, mostly in the setting of the chemotherapy of advanced, metastatic disease. In one of these, a retrospective study of 382 patients with completely resected stage 1 disease, a low pre-operative NLR predicted a lower rate of disease recurrence \[[@B21]\]. In another study, an elevated NLR was significantly associated with poor prognosis in patients with locally advanced NSCLC undergoing chemoradiation with or without surgery \[[@B22]\]. Other studies have also shown the NLR to be a useful predictor of survival in stage IV metastatic NSCLC patients undergoing chemotherapy \[[@B23],[@B24]\].

Given the emergence of PD-1-targeted immunotherapy as a priority treatment strategy in late-stage NSCLC, advance measurement of the NLR represents a potentially important prognostic strategy in both the front-line and second-line treatment settings with nivolumab. To date, however, only a few full-length publications have addressed this issue \[[@B25]\], together with one pooled analysis covering the period of 2017--2018 that also included a number of published congress abstracts, as well as full-length studies, focused on the utility of a rising NLR during or following immunotherapy \[[@B30]\]. Accordingly, the primary objective of the current study was to build on this somewhat limited database by investigating the prognostic potential of measurement of the NLR prior to administration of nivolumab to squamous and nonsquamous NSCLC patients who had failed platinum-based first-line therapy in the metastatic setting.

Study design & ethics approval {#S0001}
==============================

A retrospective, multicenter, noninterventional analysis was performed on data collected from the nivolumab Expanded Access Programme in South Africa (SA-EAP). The study investigated clinical outcomes and toxicity associated with nivolumab in patients (n = 56) with relapsed metastatic NSCLC. Each patient signed informed consent and institutional ethics approval was obtained from the Human Sciences Research Council of South Africa (Protocol Number: REC 1/20/09/17).

Materials & methods {#S0002}
===================

Patient population {#S0003}
------------------

### Inclusion criteria {#S0004}

All of the patients had locally advanced squamous or nonsquamous NSCLC confirmed either by histology or by cytology and had progressed on or after treatment following a minimum of 1 year of prior systemic treatment for stage IIIB disease or multimodal therapy for stage IV disease. Patients were aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 \[[@B31]\]. All toxicities attributed to prior anticancer therapy other than alopecia and fatigue had resolved to grade 1 according to the National Cancer Institute's (USA) Common Terminology Criteria for Adverse Events status at baseline \[[@B32]\].

### Exclusion criteria {#S0005}

Patients were excluded if they had active, known or suspected autoimmune disease, HIV, hepatitis B or C infection; symptomatic brain metastases; or had received other concurrent systemic anticancer treatments for NSCLC. At the time of enrollment, patients had a life expectancy of ≥6 weeks. Patients who had received prior therapy with an anti-PD-1- and/or anti-PD-L1-targeted monoclonal antibody, or any other antibody targeting other T-cell costimulation or checkpoint pathways were not eligible for inclusion. Additionally, patients were not be included in the program if they had a condition requiring systemic treatment with either corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days of administration of nivolumab; or if they had any known active chronic liver disease; had previous malignancies unless a complete remission was achieved at least 3 years prior to administration of nivolumab; or if the patient had not recovered from major surgery.

### Data collection {#S0006}

The participating practices and oncology centers collected and recorded the required data on patient case report forms, which were returned to the study facilitator. The collected data were electronically captured on an Excel-based capturing tool (Microsoft, WA, USA) for analysis and analyzed using RStudio software (version 3.2.3; RStudio, MA, USA).

Data from different points in time throughout a patient's medical history were reviewed. These data included four aspects of treatment history: demographic features, disease characteristics and first-line treatment and duration thereof in the nivolumab SA-EAP. The data reported included: demographic information, NSCLC subtype and stage, presence of brain or liver metastases, lactate dehydrogenase values, ECOG performance status \[[@B31]\] and previous treatments. PD-L1 status was not required at the time of entry to the EAP.

Treatment-related information included history of concomitant drug use, details of nivolumab treatment (date of first nivolumab dose, number of infusions, date of re-induction and reason for discontinuation or omission), date of first measured disease progression (PD) and overall tumor response rate after completion of induction therapy. Distribution of overall tumor response (proportion of patients with complete response \[CR\], PR, stable disease or PD) was defined according to the WHO Response Evaluation Criteria in Solid Tumors \[[@B33]\] at 12 and 24 weeks, and thereafter every 3 months for up to 2 years. Objective response rate was defined as the sum of the numbers of patients with CR and PR. Relevant biologic values and incidence and grading of adverse events were also collected using the Common Toxicity Criteria version 4 \[[@B32]\]. CRFs were received for 56 patients from six centers.

### Measurement of NLR {#S0007}

Five millilitres of EDTA-anticoagulated blood was taken from each patient and a full blood count and differential performed using automated hematology analyzers. To obtain the NLR, the total circulating neutrophil count was divided by the total circulating lymphocyte count and patients categorized in two sub-groups according to the magnitudes of their NLR values, these being NLR \<5 (n = 40 patients) and ≥5 (n = 14 patients; two patients had no data for this time point) \[[@B30]\].

### Statistical analysis {#S0008}

The collected data were statistically analyzed using descriptive statistics, with medians and ranges of continuous variables and frequencies and percentages for categorical variables. OS and progression-free survival (PFS) were estimated using the Kaplan--Meier method, with 95% CIs reported \[[@B34],[@B35]\]. A Cox proportional hazards model was used to identify covariates independently associated with survival. OS was analyzed using time from nivolumab initiation date and date of most recent visit or death, whichever occurred first. PFS was analyzed using time from nivolumab initiation date to end of follow-up, or date of first measured PD or death resulting from any cause, whichever occurred first. Patients with neither PD nor death were right censored at the last date of tumor assessment. Time to progression was defined as time from nivolumab initiation date to end of follow-up, or date of first measured PD, or treatment failure resulting from a competing risk (i.e., death). Patients without PD (or death as competing risk) were right censored at the last date of tumor assessment. NLR cut-off value of ≥5 was calculated using the receiving operating characteristic curves. The Mann--Whitney U-test was used to evaluate the significance of differences in the absolute circulating neutrophil and lymphocyte counts between the NLR \<5 and NLR ≥5 sub-groups.

Results {#S0009}
=======

Patient characteristics at baseline are shown in [Table 1](#T1){ref-type="table"}. All patients had received at least one line of prior systemic therapy for advanced disease (ranging from one to five). The median number of nivolumab treatment cycles was 10 (1--52 cycles).

###### Patient characteristics.

                         n
  ---------------------- ----------
  **Gender**              
  Male                   32 (57%)
  Female                 24 (43%)
  **Race**                
  Black                  2 (4%)
  Colored                7 (12%)
  Indian                 2 (4%)
  White                  45 (80%)
  **Smoking status**      
  Current                13 (23%)
  Former                 29 (52%)
  Never                  15 (25%)
  **ECOG PS**             
  0                      6 (11%)
  1                      44 (79%)
  2                      6 (11%)
  **Metastatic sites**    
  [Brain]{.ul}            
  Yes                    6 (11%)
  No                     50 (89%)
  [Lung]{.ul}             
  Yes                    44 (79%)
  No                     12 (21%)
  [Liver]{.ul}            
  Yes                    3 (5%)
  No                     53 (95%)
  [Bone]{.ul}             
  Yes                    16 (29%)
  No                     40 (71%)
  [Skin]{.ul}             
  Yes                    2 (4%)
  No                     54 (96%)
  [Lymph nodes]{.ul}      
  Yes                    40 (71%)
  No                     16 (29%)
  [Other]{.ul}            
  Yes                    10 (18%)
  No                     46 (82%)

ECOG: Eastern Cooperative Oncology Group.

Efficacy {#S0010}
--------

These results are shown in [Table 2](#T2){ref-type="table"}. With respect to the entire group of patients (n = 56), responses were documented in a total of 13 (24%) patients. There were two CRs (4%, 95% CI: 0--8%) and 11 PRs (20%, 95% CI: 9--30%). As shown in [Figure 1](#F1){ref-type="fig"}A, the median PFS was 6 months (95% CI: 4--8 months), while the 1-year PFS rate was 25% (95% CI: 14--36%). As shown in [Figure 1](#F1){ref-type="fig"}B, the median OS (n = 56) was 11 months (95% CI: 7--16 months), and the 1-year survival rate was 45% (95% CI: 32--58%). The 2-year survival rate was 32% (95% CI: 20--45%).

###### Rate response.

  Response   Number of responses   Percentage (95% CI)
  ---------- --------------------- ---------------------
  CR         2                     4% (0--8%)
  PR         11                    20% (9--30%)
  SD         18                    32% (20--44%)
  PD         22                    39% (26--52%)
  NE         3                     5% (0--11%)

CR: Complete response; NE: Not evaluable; PD: Disease progression; PR: Partial response; SD: Stable disease.

![Progression-free survival and overall survival for patients treated with nivolumab.\
**(A)** Kaplan--Meier plot for progression-free survival. **(B)** Kaplan--Meier plot for OS.\
OS: Overall survival.](lmt-09-37-g1){#F1}

Neutrophil/lymphocyte ratio {#S0011}
---------------------------

Pretreatment NLRs were analyzed for associations with the same outcomes using landmark survival analyses and time-dependent Cox regression models. A univariate analysis tested the association of NLR with OS. As shown in [Figure 2](#F2){ref-type="fig"}, the median OS values for the NLR \<5 and ≥5 and sub-groups of patients were 14.5 and 7.02 months, respectively (log rank test = 9.04, p = 0.002635). The absolute neutrophil and lymphocyte counts for the NLR \<5 and ≥5 subgroups are shown in [Table 3](#T3){ref-type="table"} and demonstrate significantly lower and higher counts of each cell type, respectively, in the NLR \<5 sub-group.

![Survival by baseline neutrophil/lymphocyte ratio.](lmt-09-37-g2){#F2}

###### Median absolute circulating neutrophil and lymphocyte counts according to neutrophil/lymphocyte ratio category.

  Leukocyte type (cells × 10^3^/ml blood)   NLR \<5 (n = 40)   NLR ≥5 (n = 14)      p-value
  ----------------------------------------- ------------------ -------------------- ---------
  Neutrophils                               3.89 (1--9.26)     5.50 (3.47--27.61)   \<0.001
  Lymphocytes                               1.48 (0.28--4.3)   0.71 (0.4--1.61)     \<0.001

NLR: Neutrophil/lymphocyte ratio.

Other variables tested on univariate analysis {#S0012}
---------------------------------------------

These results are shown in [Figures 3](#F3){ref-type="fig"}A--C, respectively. In the case of categorization of the pretreatment number of metastatic sites, those patients with up to 2 or 3--6 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (log rank test = 6.33; p = 0.01185). The median OS values for males and females were 10.3 and 14.5 months, respectively (log rank test = 1.86; p = 0.1726). With respect to the pretreatment ECOG PS, the median survival times of patients with values of 0 or 1 compared with those with a value of 2 were 11.21 and 7.44 months, respectively (log rank test = 0.73; p = 0.3943).

![Overall survival by number of metastatic sites, gender and ECOG performance status.\
**(A)** Survival by number of metastatic sites. **(B)** Survival by number of gender. **(C)** Survival by ECOG performance status.\
ECOG: Eastern Cooperative Oncology Group.](lmt-09-37-g3){#F3}

Multivariate Cox regression analysis for OS {#S0013}
-------------------------------------------

A multivariate Cox regression analysis revealed that baseline NLR ≥5 was the only variable associated with OS (hazard ratio = 2.3209; p \<0.0447). As shown in [Table 4](#T4){ref-type="table"}, the model included four variables: NLR, gender, number of metastatic sites and ECOG PS.

###### Multivariate Cox-regression analysis for overall survival.

  Variable                                    Hazard ratio   p-value
  ------------------------------------------- -------------- ---------
  Baseline NLR (\<5 vs ≥5)                    2.3209         0.0447
  Gender (male vs female)                     0.7162         0.3776
  ECOG (0&1 vs 2)                             1.7101         0.2847
  Number of metastatic sites (1--2 vs 3--6)   2.3183         0.1338

ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil/lymphocyte ratio.

Toxicity & immune-related adverse events {#S0014}
----------------------------------------

The documented frequencies and severities of nivolumab immune-related adverse events (IrAEs) are summarized in Supplementary Table 1. These toxicities were similar to those reported by other investigators for this patient population \[[@B11]\]. The most commonly documented IrAEs included fatigue, skin rash, diarrhea with and without colitis, pneumonitis and endocrine \[[@B32]\].

Discussion {#S0015}
==========

This retrospective analysis of the entire SA-EAP cohort of 56 patients with advanced NSCLC demonstrated that treatment with nivolumab achieved a median OS of 11 months (95% CI: 7--16 months), a 1-year OS of 45% (95% CI: 22--58%) and a 2 year OS of 32% (95% CI: 20--45%). Importantly, categorization of patients into two sub-groups based on pretreatment NLR values of \<5 and ≥5 revealed a clear and significant distinction with respect to median OS, these being 14.5 and 7.02 months in the low and high NLR sub-groups, respectively (p = 0.002635). Not surprisingly, patients in the NLR \<5 sub-group had significantly lower and higher absolute circulating neutrophil and lymphocyte counts, respectively, than those in the NLR ≥5 sub-group of patients. As revealed by Cox regression analysis, the baseline NLR was a stronger predictor of OS than other variables such as number of metastatic sites, ECOG performance status and gender. These findings are consistent with the increasing realization that the neutrophil, seemingly in relation to numbers, subtype and activation status of these cells, represents an impediment to various types of anticancer therapy, including checkpoint-targeted therapy \[[@B21],[@B36]\].

In this context, recruitment and reprogramming of neutrophils feature prominently as mechanisms utilized by advanced malignancies to augment the immunosuppressive milieu of the tumor microenvironment (TME), enabling tumor growth and spread. Recruitment of neutrophils to the TME is achieved via production of the myeloid growth factor, G-CSF by tumors. Granulocyte colony-stimulating factor-mediated accelerated neutrophil production in the bone marrow, together with release of tumor-derived, neutrophil-attracting chemokines, particularly CXCL5 and CXCL8, promotes influx of neutrophils into the TME \[[@B37],[@B39]\]. On entering the TME, tumor-associated neutrophils encounter a cytokine environment that favors the transition of these cells to a highly immunosuppressive, protumorigenic phenotype. These reprogrammed neutrophils are known variously as T-lymphocyte-suppressive neutrophils, polymorphonuclear leukocyte-myeloid-derived suppressor cells or type N2 protumorigenic neutrophils \[[@B37],[@B39]\]. The most prominent cytokine involved in promoting the transition of these cells to a protumorigenic phenotype is TGFβ1 derived from various types of immune cells that populate the TME, including MDSCs *per se*, regulatory T cells (Tregs) and M2-like macrophages.

Neutrophil-mediated immunosuppression in the TME results primarily from the potent inhibitory effects of these cells on the proliferation and antitumor activity of tumor-infiltrating lymphocytes, and are achieved largely, but not exclusively, by pro-oxidative mechanisms \[[@B37],[@B39]\]. In addition, these protumorigenic neutrophils have also been reported to exclude antitumor CD8^+^ T cells from the tumor mass in patients with advanced NSCLC and to impede the efficacy of PD-1-targeted immunotherapy \[[@B40]\]. This latter observation is consistent with the findings of the current study that neutrophils are an impediment to the efficacy of tumor-targeted immunotherapy.

Notwithstanding the prognostic utility of pretreatment measurement of the NLR in patients with NSCLC assigned to receive nivolumab, an elevated pretherapy NLR, as mentioned earlier, is also associated with decreased efficacy of chemotherapy and chemo-radiation with or without surgery in patients with advanced NSCLC \[[@B21]\]. In addition, increased numbers of circulating neutrophils are predictive of poor responsiveness to radiation therapy *per se* in patients with other types of malignancy such as cancer of the cervix \[[@B36]\]. In this context, the prognostic utility of the NLR in the settings of the chemotherapy and radiation therapy of NSCLC is not surprising given that the recently discovered process of immunogenic cell death contributes to the therapeutic efficacy of certain types of platinum-based chemotherapeutic agents, as well as radiation \[[@B41]\]. This suggests that pretreatment measurement of the NLR will have prognostic potential in the setting of PD-1-targeted immunotherapy even when used in combination with chemotherapy and/or radiation therapy of patients with advanced NSCLC, as well as other types of metastatic cancers.

With respect to limitations of our study, these include the retrospective design, unavailability of PD-L1 levels, the complexities in controlling for selection bias and the lack of a control group. It must be noted, however, that measurement of PD-L1 levels was not a requirement for enrolment of a patient on the SA-EAP at the time of the study design. In addition, a proportion of our patients did not complete nivolumab treatment because of early PD. Some of these patients may have had a limited life expectancy due to advanced cancer. In this context, it is noteworthy that patients with advanced NSCLC have limited therapeutic options and are frequently over-treated with potentially harmful medications, underscoring the need to prioritize innovative approaches to optimize current therapies. Despite the aforementioned limitations of our study, we do believe, therefore, that our findings have contributed to the increasing awareness of the prognostic value of pretreatment measurement of the NLR in identifying patients with advanced NSCLC who are most likely to benefit from PD-1-targeted immunotherapy. These findings must, however, be confirmed in stringently controlled prospective clinical trials in order to conclusively validate the predictive utility of NLR as a biomarker. In this regard, NLR could be added to other biomarkers already incorporated in the clinical management of NSCLC such as PD-L1 and tumor mutational burden.

Even in the case of those who are least likely to respond well to immune checkpoint-targeted therapy based on an NLR value of ≥5, early identification may qualify such patients for adjunctive neutrophil-targeted therapies, many of which are in the early stages of clinical evaluation \[[@B37],[@B39],[@B42]\] but again this contention is subject to stringent validation.

Conclusion {#S0016}
==========

Our study suggests that a pretreatment NLR score of ≥5 is associated with a poor outcome in patients with recurrent metastatic NSCLC treated with nivolumab. Importantly, inclusion of this rapid and affordable biomarker can easily be introduced into routine clinical practice in order to categorize NSCLC patients undergoing treatment with immune-checkpoint inhibitors according to probable prognosis. However, rigorous prospective studies are needed to validate the potential predictive role of NLR in guiding treatment decisions, patient selection and clinical trial design.

###### Summary points

-   The neutrophil/lymphocyte ratio (NLR) has prognostic potential in different types of cancer treated with various therapeutic modalities (chemotherapy, radiation and surgery).

-   Patients with advanced non-small-cell lung cancer are major beneficiaries of programmed cell death protein 1 (PD-1)-targeted immunotherapy.

-   Tumor-infiltrating neutrophils appear to be an impediment to this type of immunotherapy.

-   The NLR is a biomarker of cancer-related inflammation and may predict poor responsiveness to immunotherapy in non-small-cell lung cancer.

-   In the current study, a NLR of ≥5 measured at the time of initiation of nivolumab therapy was associated with a significantly decreased overall survival relative to those patients with a NLR of \<5.

-   Patients with NLR values of ≥5 had significantly increased numbers of circulating neutrophils and decreased numbers of lymphocytes relative to those with NLR values of \<5.

-   Of all the variables included in a multivariate Cox regression analysis of determinants of overall survival, NLR ≥5 was identified as the only independent prognostic factor.

-   Measurement of the NLR is an easily accessible and inexpensive prognostic tool for medical practitioners.
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